Collectively, selective and effective regulating antitumor T‐cell immune‐specific responses for anticancer therapy are essential to inhibit CRC cells, and TNF is used as an immune‐cytokine tumor necrosis factor in combination with chemotherapeutic agents, and could provide clues for sensitizing resistant tumors to immune checkpoint blockade therapy. The gene discussed is TNF; the disease is colorectal carcinoma.